Clonazepam as a therapeutic adjunct to improve the management of depression: a brief review
β Scribed by Shigeru Morishita
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 144 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0885-6222
- DOI
- 10.1002/hup.1015
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Clonazepam, first used for seizure disorders, is now increasingly used to treat affective disorders. We summarize the use of clonazepam to improve the management of depression. Clonazepam is useful for treatmentβresistant and/or protracted depression, as well as for acceleration of response to conventional antidepressants. Clonazepam is at this time recommended for use in combination with SSRIs (fluoxetine, fluvoxamine, sertraline) as an antidepressant, and should be used at a dosage of 2.5β6.0βmg/day. If clonazepam is effective, a response should be observed within 2β4 weeks. It is significantly more effective for unipolar than for bipolar depression. Lowβdose, longβterm treatment with clonazepam exhibits a prophylactic effect against recurrence of depression. Although the mechanism of action of clonazepam has not yet been established, some investigators have been suggested that it involves enhancement of antiβanxiety effects, anticonvulsant effects on subclinical epilepsy, increase in 5βHT/monoamine synthesis or decrease in 5βHT receptor sensitivity mediated through the GABA system, and regulate in GABA activity. Copyright Β© 2009 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
## Abstract ## Objectives To explore the feasibility and effectiveness of brief interventions to prevent depression in older subjects. ## Method MEDLINE, PsycINFO and HealthStar were searched for potentially relevant articles published from January 1966 to June 2003, January 1974 to June 2003 an
We describe two patients with the catastrophic antiphospholipid syndrome associated with elevation of β€ 2glycoprotein I antibodies and fulminant thrombotic diatheses. Both patients were treated with therapeutic plasma exchange (TPE), which resulted in a marked decrease in antibody titer accompanied